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Summary for lay people: Patients who survive coma may develop disorders of 
consciousness. Treating these patients to improve recovery is extremely challenging. 
Apomorphine, a drug which stimulates dopamine neurons, exhibits promising clinical effects 
and safety in preliminary studies. However, its efficacy for the recovery of consciousness in 
large studies and its neural mechanisms remain to be definitely demonstrated. This trial aims 
to quantify the efficacy of apomorphine in treating patients with disorders of consciousness and 
to identify the brain networks it targets, using standardized clinical scales and advanced brain 
imaging techniques. Confirmatory results would open new and much needed therapeutic 
options for brain-injured patients. 
 
Background: Patients who survive severe brain injury may develop chronic disorders of 
consciousness. Treating these patients to improve recovery is extremely challenging because 
of the absence of international guidelines and scarce therapeutic options (Schnakers and 
Monti, 2017). 
Among pharmacological treatments, apomorphine, a potent direct non-specific dopamine 
agonist with a high affinity for D2 receptors, has exhibited promising behavioral effects and 
safety of use in small-sample pilot studies (Fridman et al., 2009, 2010). However, despite the 
improvement compared to historical data, the lack of a control group could not eliminate the 
possibility that the effect was a result of spontaneous recovery, and the true efficacy of 
apomorphine for the recovery of consciousness remains unclear (Gosseries et al., 2014). In 
addition, the underlying neural mechanisms of this treatment are still unknown. An upregulation 
of central thalamic activity through a modulation of the anterior forebrain mesocircuit has been 
proposed as a possible explanation (Schiff, 2010a, 2010b) but the absence of neuroimaging 
and neurophysiological data prevent definitive confirmation. This clinical trial aims to 1) verify 
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and quantify the efficacy of apomorphine subcutaneous infusion in patients with disorders of 
consciousness, 2) better identify the rate and the phenotype of responders to treatment, 3) 
evaluate tolerance and side effects occurrence in this specific patient population and 4) 
investigate the neural networks underlying its modulating action on consciousness using 
multimodal outcome measurements. 
 
Methods/design: This study is a prospective double-blind randomized placebo-controlled trial. 
Forty-eight patients diagnosed with disorders of consciousness (i.e., unresponsive wakefulness 
syndrome and minimally conscious state) will be randomized to receive a 30-day regimen of 
either apomorphine hydrochloride or placebo via daily 12-hour subcutaneous infusions. 
Patients will be monitored at baseline 30 days before initiation of therapy, during treatment and 
for 30 days after treatment washout, followed by a two-year remote follow-up. In an initial study 
phase, up to six patients will be treated in an open-label fashion. 
Behavioral outcome measures will include weekly assessments using standardized scales 
such as the Coma Recovery Scale – Revised (CRS-R) (Giacino et al., 2004) and the 
Nociception Coma Scale – Revised (NCS-R) (Chatelle et al., 2012) during the inpatient phase. 
Tolerance and safety of use will be monitored using a specifically designed Adverse Events 
Questionnaire filled weekly by the referent physician, from treatment initiation to the end of the 
inpatient phase. Long-term behavioral follow-up will be performed at 6, 12 and 24 months post-
treatment by telephone interview using the Glasgow Outcome Scale – Extended (GOS-E) 
(Levin et al., 2001) as well as phone-adapted versions of the CRS-R and the Adverse Events 
Questionnaire. 
Neurophysiological and neuroimaging measures will complement clinical evaluations and 
provide data on brain activity. Resting-state high-density electroencephalography (EEG) will be 
acquired weekly during the whole inpatient phase. In addition, participants will be assessed 
before and after treatment with Magnetic Resonance Imaging (MRI), Positron Emission 
Tomography (PET), EEG during auditory paradigms and 24-hours EEG recordings. 
To measure changes in circadian rhythm, body core temperature (Matsumoto et al., 2013) and 
body movements (Cruse et al., 2013) will be recorded with non-invasive portable devices 
throughout the whole duration of the inpatient phase (Figure 1). 
Statistical analyses will be performed blindly to detect changes in behavioral status, circadian 
rhythmicity, brain metabolism and functional connectivity both at the individual level (comparing 
before and after treatment) and at the group level (comparing the apomorphine and the placebo 
arms). Behavioral response will be determined by changes of diagnosis using the CRS-R, and 
further analyses will also look at changes between the non-responding and the responding 
patient subgroups. Age, gender, etiology, time since injury and diagnosis will also be included 
as regressors. 
 
Hypotheses: Based on the mesocircuit hypothesis, we postulate a modulation in the activity of 
the network’s anterior forebrain structures following administration of apomorphine (Figure 2), 
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which will translate into the following changes: 1) A behavioral improvement such that the CRS-
R diagnosis and total score will improve in responding patients, while NCS-R scores may also 
increase, reflecting a higher perception of pain; along with long-term functional recovery 
measured by sustained higher GOS-E and CRS-R scores at follow-up compared to the placebo 
group; 2) A relative recovery of sleep-wake cycles measured by a normalization of circadian 
rhythmicity as well as an increase in total body movements; 3) A metabolic improvement with 
significant increase of whole-brain glucose uptake, with highest increase of values found in the 
striatum, thalamus and frontoparietal cortical areas measured with PET; 4) A modulation of 
dynamic connectivity in response to apomorphine measured by resting-state fMRI analyses 
(seed-based and whole-brain connectivity measures) and changes of resting-state EEG 
connectivity metrics (notably increased mean alpha spectral connectivity, participation 
coefficient and delta modularity).  
Additionally, we can expect improvements after treatment in less specific measures of recovery 
such as sleep cycle architecture on 24-hours EEG hypnograms and the probability of 
consciousness given by a machine learning multivariate classifier derived from EEG recordings 
during auditory paradigms (Engemann et al., 2015). 
While improvements can be expected as well in the placebo arm due to spontaneous recovery 
and placebo effect, we hypothesize that responding patients in the apomorphine arm will exhibit 
significantly higher increases in these different markers of recovery. 
 
Discussion: New multimodal approaches using neurophysiology and neuroimaging allow a 
more accurate diagnosis of patients with disorders of consciousness but the current available 
treatments remain inefficient. This study aims to verify the efficacy of apomorphine for the 
recovery of consciousness in the first randomized placebo-controlled double-blind trial using 
multimodal measurement methods. The results will contribute to define the role of dopamine 
agonists in the treatment of this challenging population of patients and help identify the neural 
underpinnings underlying the modulation of consciousness networks by apomorphine. Notably, 
this trial is designed to bring objective neuroimaging and neurophysiological evidence to further 
assess the validity of the mesocircuit hypothesis and its modulation by pharmacological agents, 








Figure 1. Timeline of the study protocol. * : multimodal assessment; Blue segments: inpatient 
phase; Green segment: outpatient follow-up; CRS-R: Coma Recovery Scale – Revised; NCS-
R: Nociception Coma Scale – Revised; EEG: electroencephalography; PET: positron emission 
tomography; MRI: magnetic resonance imaging; T°: body core temperature; GOS-E: Glasgow 




Figure 2. The mesocircuit hypothesis. (A) Normal wakeful condition. Dopamine neurons in the 
striatum inhibit the pallidum, which prevents it from inhibiting the thalamus. Thalamic 
projections activate cortical networks and get positive feedback in return. Excitatory inputs from 
both the cortex and the thalamus activate the striatum to maintain the loop. (B) Brain injury. 
Withdrawal of thalamostriatal and corticostriatal projections following widespread neuronal 
deafferentation leads to reduced activity of the striatum, resulting in an inhibition of thalamic 
activity and decreased cortical activation. (C) Postulated action of apomorphine (APO) on brain 
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injury. The facilitating action of apomorphine on striatal dopamine neurons could substitute for 
the missing inputs and restore the inhibitory striatopallidal projections, thus freeing the thalamus 
and its output towards the cortex. 
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